European Journal of Clinical Pharmacology

, Volume 68, Issue 5, pp 853–856

Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine

  • David M. Wood
  • Susannah Davies
  • Malgorzata Puchnarewicz
  • Atholl Johnston
  • Paul I. Dargan
Pharmacoepidemiology and Prescription

Abstract

Purpose

Long-term regular use of ketamine has been reported to be associated with severe symptomatic urinary tract problems. Methoxetamine, an arylcyclohexylamine derivative of ketamine, is marketed as a “bladder safe” derivative of ketamine, and no cases of acute toxicity following analytically confirmed methoxetamine use have been reported to date. We report here a case series of three individuals with acute toxicity related to the analytically confirmed use of methoxetamine.

Case series

Three patients aged between 28 and 42 years presented to the Emergency Department (ED) on unrelated occasions having used methoxetamine. Clinical features were suggestive of a “dissociative/catatonic” state similar to that seen with ketamine; in addition, they had clinical features of acute sympathomimetic toxicity with significant tachycardia and hypertension. All were managed with low-dose benzodiazepines and discharged home once their symptoms/signs had settled.

Toxicological screening

Serum collected at the time of presentation to the ED was analysed qualitatively and quantitatively by gas chromatography–mass spectrometry. Serum concentrations ranged from 0.09 to 0.2 mg/L; in addition, detectable levels of 6-APB/5-APB were found in one of the patients.

Conclusions

These three analytically confirmed cases demonstrate that acute methoxetamine-related toxicity is associated with both “dissociative” and “sympathomimetic” clinical features. The information from these three cases is useful to clinical pharmacologists, not only in managing individuals with acute methoxetamine toxicity but also in advising the appropriate legislative authorities on the risk of acute harm related to methoxetamine use. Further work is needed to determine whether methoxetamine is more “bladder friendly” than ketamine, as has been suggested by those marketing methoxetamine.

Keywords

Methoxetamine Ketamine Acute toxicity Recreational drug 

References

  1. 1.
    European Monitoring Centre for Drugs and Drug Addiction (2010) Annual report 2010: The state of the drugs problem in Europe. Available from: www.emcdda.europa.eu/attachements.cfm/att_120104_EN_EMCDDA_AR2010_EN.pdf. Accessed 25 Oct 2011
  2. 2.
    United Nations Office on Drugs and Crime (2011) World drug report 2011. Available from: www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf. Accessed 25 Oct 2011
  3. 3.
    Chu PS, Kwok SC, Lam KM, Chu TY, Chan SW, Man CW, Ma WK, Chui KL, Yiu MK, Chan YC, Tse ML, Lau FL (2007) 'Street ketamine'-associated bladder dysfunction: a report of ten cases. Hong Kong Med J 13:311–313PubMedGoogle Scholar
  4. 4.
    Chu PS, Ma WK, Wong SC, Chu RW, Cheng CH, Wong S, Tse JM, Lau FL, Yiu MK, Man CW (2008) The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 102:1616–1622PubMedCrossRefGoogle Scholar
  5. 5.
    Colebunders B, Van Erps P (2008) Cystitis due to the use of ketamine as a recreational drug: a case report. J Med Case Rep 2:219CrossRefGoogle Scholar
  6. 6.
    Shahani R, Streutker C, Dickson B, Stewart RJ (2007) Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69:810–812PubMedCrossRefGoogle Scholar
  7. 7.
    Tsai TH, Cha TL, Lin CM, Tsao CW, Tang SH, Chuang FP, Wu ST, Sun GH, Yu DS, Chang SY (2009) Ketamine-associated bladder dysfunction. Int J Urol 16:826–829PubMedCrossRefGoogle Scholar
  8. 8.
    Wood D, Cottrell A, Baker SC, Southgate J, Harris M, Fulford S, Woodhouse C, Gillatt D (2011) Recreational ketamine: from pleasure to pain. BJU Int 107:1881–1884PubMedCrossRefGoogle Scholar
  9. 9.
    Mak SK, Chan MT, Bower WF, Yip SK, Hou SS, Wu BB, Man CY (2011) Lower urinary tract changes in young adults using ketamine. J Urol 186:610–614PubMedCrossRefGoogle Scholar
  10. 10.
    Kalsi SS, Wood DM, Dargan PI (2011) The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Heal Threat J 4:7107Google Scholar
  11. 11.
    UK Advisory Council on the Misuse of Drugs (ACMD) (2011) Consideration of the novel psychoactive substances (‘legal highs’). Available from: http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/acmdnps2011?view=Binary. Last accessed 25 Oct 2011
  12. 12.
    Morris H (2011). Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist. Vice Magazine 11 Feb 2011. Available from: www.vice.com/read/interview-with-ketamine-chemist-704-v18n2. Accessed 25 Oct 2011)
  13. 13.
    Ward J, Rhyee S, Plansky J, Boyer E (2011) Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol (Phila). doi:10.3109/15563650.2011.617310
  14. 14.
    Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R, Holt DW, Dargan PI (2010) Purchasing 'legal highs' on the Internet—is there consistency in what you get? Q J Med 103:489–493CrossRefGoogle Scholar
  15. 15.
    Ramsey J, Dargan PI, Smyllie M, Davies S, Button J, Holt DW, Wood DM (2010) Buying 'legal' recreational drugs does not mean that you are not breaking the law. Q J Med 103:777–783CrossRefGoogle Scholar
  16. 16.
    Brandt SD, Sumnall HR, Measham F, Cole J (2010) Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2:377–382PubMedCrossRefGoogle Scholar
  17. 17.
    Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol (Phila) 49:499–505CrossRefGoogle Scholar
  18. 18.
    Yeung LY, Rudd JA, Lam WP, Mak YT, Yew DT (2009) Mice are prone to kidney pathology after prolonged ketamine addiction. Toxicol Lett 191:275–278PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • David M. Wood
    • 1
    • 2
    • 3
  • Susannah Davies
    • 4
  • Malgorzata Puchnarewicz
    • 4
  • Atholl Johnston
    • 5
  • Paul I. Dargan
    • 1
    • 2
  1. 1.Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and Kings Health PartnersLondonUK
  2. 2.King’s College LondonLondonUK
  3. 3.Medical Toxicology OfficeGuy’s HospitalLondonUK
  4. 4.Analytical Services International Ltd, St George’sUniversity of LondonLondonUK
  5. 5.Clinical Pharmacology, Barts and The London School of Medicine and Dentistry, Queen Mary, University of LondonLondonUK

Personalised recommendations